Article
Oncology
Jonathan Welti, Adam Sharp, Nigel Brooks, Wei Yuan, Christopher McNair, Saswati N. Chand, Abhijit Pal, Ines Figueiredo, Ruth Riisnaes, Bora Gurel, Jan Rekowski, Denisa Bogdan, William West, Barbara Young, Meera Raja, Amy Prosser, Jordan Lane, Stuart Thomson, Jenny Worthington, Stuart Onions, Jonathan Shannon, Silvia Paoletta, Richard Brown, Don Smyth, Gareth W. Harbottle, Veronica S. Gil, Susana Miranda, Mateus Crespo, Ana Ferreira, Rita Pereira, Nina Tunariu, Suzanne Carreira, Antje J. Neeb, Jian Ning, Amanda Swain, David Taddei, Matthew J. Schiewer, Karen E. Knudsen, Neil Pegg, Johann S. de Bono
Summary: The resistance to AR blockade in CRPC is associated with sustained AR signaling through alternative splicing of AR (AR-SV). Inhibitors of transcriptional coactivators like p300/CBP are attractive therapeutic targets for lethal prostate cancer. CCS1477, a novel small-molecule inhibitor of p300/CBP, shows promise in inhibiting cell proliferation in prostate cancer cell lines and regulating AR and C-MYC signaling.
Article
Plant Sciences
Yanhua Chen, Qianqian Zhou, Hong Zhang, Linfan Xu, Lianheng Lu, Bing Shu, Lihong Zhou, Fuwen Yuan
Summary: This study aims to explore the anti-tumor role and potential mechanism of Qingdai Decoction (QDT) on prostate cancer. The results showed that QDT can repress cancer growth in advanced prostate cancer models in an androgen receptor independent manner by targeting NOS3, TGFB1, and NCOA2.
JOURNAL OF ETHNOPHARMACOLOGY
(2023)
Article
Multidisciplinary Sciences
A. M. Mahedi Hasan, Paolo Cremaschi, Daniel Wetterskog, Anuradha Jayaram, Stephen Q. Wong, Scott Williams, Anupama Pasam, Anna Trigos, Blanca Trujillo, Emily Grist, Stefanie Friedrich, Osvaldas Vainauskas, Marina Parry, Mazlina Ismail, Wout Devlies, Anna Wingate, Mark Linch, Cristina Naceur-Lombardelli, Charles Swanton, Mariam Jamal-Hanjani, Stefano Lise, Shahneen Sandhu, Gerhardt Attard
Summary: By analyzing the genomic complexity of AR across lethal metastases from 10 prostate cancer patients, the study finds diverse and patient-specific AR gene alterations, as well as independent acquisition of related genomic changes within an individual and the existence of AR-neutral clones. The study also confirms a common clone of origin across metastases and identifies clusters of metastases with diverged autosomal copy number alterations. These findings provide insights into the heterogeneity and evolution of AR alterations in metastatic prostate cancer.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Xun Shangguan, Zehua Ma, Minghao Yu, Jie Ding, Wei Xue, Jun Qi
Summary: This study reveals a dependence on SQLE-mediated cholesterol metabolism in castration-resistant prostate cancer with PTEN and p53 deficiency, providing insights for new therapeutic strategies.
Article
Oncology
Zemin Hou, Shengsong Huang, Zhenfei Li
Summary: Androgens are crucial in the development of prostate cancer, and targeting steroidogenesis and the androgen receptor has been effective in delaying disease progression. New generation androgen receptor pathway inhibitors like abiraterone and enzalutamide continue to emphasize the role of the androgen-AR axis, even in cases of resistance. The importance of this axis in managing the disease after resistance to current treatments, particularly in neuroendocrine prostate cancer, remains uncertain.
Article
Biochemistry & Molecular Biology
Meng Xiao He, Michael S. Cuoco, Jett Crowdis, Alice Bosma-Moody, Zhenwei Zhang, Kevin Bi, Abhay Kanodia, Mei-Ju Su, Sheng-Yu Ku, Maria Mica Garcia, Amalia R. Sweet, Christopher Rodman, Laura DelloStritto, Rebecca Silver, John Steinharter, Parin Shah, Benjamin Izar, Nathan C. Walk, Kelly P. Burke, Ziad Bakouny, Alok K. Tewari, David Liu, Sabrina Y. Camp, Natalie I. Vokes, Keyan Salari, Jihye Park, Sebastien Vigneau, Lawrence Fong, Joshua W. Russo, Xin Yuan, Steven P. Balk, Himisha Beltran, Orit Rozenblatt-Rosen, Aviv Regev, Asaf Rotem, Mary-Ellen Taplin, Eliezer M. Van Allen
Summary: The study revealed pervasive coexpression of androgen receptor isoforms in cancer cells and explored the mechanisms of treatment resistance in metastatic castration-resistant prostate cancer.
Article
Multidisciplinary Sciences
Tao Shen, Bingning Dong, Yanling Meng, David D. Moore, Feng Yang
Summary: GATA2 degradation driven by COP1 is a direct mechanism for regulating AR expression and activation, PCa growth, and castration resistance.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Multidisciplinary Sciences
Shawn C. Chafe, Frederick S. Vizeacoumar, Geetha Venkateswaran, Oksana Nemirovsky, Shannon Awrey, Wells S. Brown, Paul C. McDonald, Fabrizio Carta, Andrew Metcalfe, Joanna M. Karasinska, Ling Huang, Senthil K. Muthuswamy, David F. Schaeffer, Daniel J. Renouf, Claudiu T. Supuran, Franco J. Vizeacoumar, Shoukat Dedhar
Summary: The study identified a redox homeostasis network involving the iron-sulfur cluster enzyme NFS1 in the survival mechanisms governed by the tumor hypoxia-induced pH regulator CAIX. Targeting CAIX while depleting NFS1 or blocking cyst(e)ine availability enhanced ferroptosis and inhibited tumor growth significantly. Altering intracellular pH and iron homeostasis through inhibiting CAIX activity may lead to the development of innovative therapeutic strategies for solid tumors to overcome hypoxia- and acidosis-mediated tumor progression and therapeutic resistance.
Review
Biochemistry & Molecular Biology
Rahul Advani, Sara Luzzi, Emma Scott, Caroline Dalgliesh, Joachim Weischenfeldt, Jennifer Munkley, David J. Elliott
Summary: This article discusses the expression of splicing regulators ESRP1 and ESRP2 in aggressively proliferating primary prostate tumors as markers of disease progression. It suggests that ESRP1 and ESRP2 act as lineage survival oncogenes in prostate cancer and highlights the need to identify the gene expression targets controlled by these regulators to develop targeted therapies.
Article
Oncology
Peng Jin, Lielin Wu, Gang Zhang, Bo Yang, Bisong Zhu
Summary: PDZRN4 plays a suppressive role in the growth and development of prostate cancer and may serve as a potential target for biochemical therapy in hormone-resistant PC.
Article
Oncology
Mohammad Waseem, Himali Gujrati, Bi-Dar Wang
Summary: In this study, the researchers investigated the role of the miR-99b-5p/mTOR/AR/SMARCD1 signaling axis in African American (AA) prostate cancer (PCa) aggressiveness. They found that nuclear mTOR, AR, and SMARCD1 were highly expressed in AA PCa cells compared to European American (EA) PCa cells. miR-99b-5p inhibited the protein levels of mTOR, AR/AR-V7, and SMARCD1 in the cytoplasm and nuclei of both EA and AA PCa cells, and effectively inhibited cell proliferation/survival and induced cell apoptosis. Additionally, the combination of miR-99b-5p and enzalutamide synergistically enhanced cytotoxicity against aggressive AA PCa and castration-resistant prostate cancer (CRPC).
FRONTIERS IN ONCOLOGY
(2023)
Article
Cell Biology
Katie Joanna Miller, Mohammad Asim
Summary: The androgen receptor (AR) signalling pathway plays a key role in prostate cancer. Upstream kinases promote AR signalling, while other kinases are regulated by AR. These kinases represent potential therapeutic targets for PCa.
Article
Biochemistry & Molecular Biology
Chaima Cherif, Dang Tan Nguyen, Clement Paris, Thi Khanh Le, Thibaud Sefiane, Nadine Carbuccia, Pascal Finetti, Max Chaffanet, Abdessamad El Kaoutari, Julien Vernerey, Ladan Fazli, Martin Gleave, Mohamed Manai, Philippe Barthelemy, Daniel Birnbaum, Francois Bertucci, David Taieb, Palma Rocchi
Summary: Menin (MEN1) protein is highly regulated by HSP27, overexpressed in high-grade PC and CRPC, and high MEN1 mRNA expression is associated with decreased biochemical relapse-free and overall survival. Silencing Menin helps inhibit CRPC cell proliferation, tumor growth, and restore chemotherapeutic sensitivity.
Article
Oncology
Yara Rodriguez, Kenji Unno, Mihai I. Truica, Zachary R. Chalmers, Young A. Yoo, Rajita Vatapalli, Vinay Sagar, Jindan Yu, Barbara Lysy, Maha Hussain, Huiying Han, Sarki A. Abdulkadir
Summary: This study identifies PRRX2 as a driver of enzalutamide resistance in prostate cancer. PRRX2 expression is highest in double-negative prostate cancer cases and its associated gene signature can serve as a biomarker for enzalutamide resistance, which can be reversed with CDK4/6 and BCL2 inhibitors.
Review
Biochemistry & Molecular Biology
Vivek Makwana, Santosh Rudrawar, Shailendra Anoopkumar-Dukie
Summary: Hexosamine biosynthetic (HBP) and PI3K/AKT/mTOR pathways play crucial roles in the proliferation and survival of prostate cancer cells by increasing androgen receptor expression and protein levels. Inhibition of a single pathway is insufficient to halt disease progression, suggesting that targeting multiple pathways at common junctions may be beneficial for effective management of prostate cancer.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2021)
Article
Oncology
Jessica L. Janes, Matthew J. Boyer, John P. Bennett, Vanessa M. Thomas, Amanda M. De Hoedt, David K. Edwards, Purva K. Singla, John M. Abran, Tamer Aboushwareb, Joseph K. Salama, Stephen J. Freedland
Summary: The study aimed to analyze whether the Oncotype DX Genomic Prostate Score (GPS) assay is associated with time to biochemical failure, distant metastasis, and prostate cancer-related death in men with localized prostate cancer undergoing external beam radiation therapy (EBRT), and whether this association is modified by race. The results showed that GPS results are strongly associated with these endpoints and that the association remains consistent across different races.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Editorial Material
Oncology
Nadine A. Friedrich, Stephen J. Freedland, Ilona Csizmadi
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Review
Urology & Nephrology
Farnoosh Nik-Ahd, Andrew Jarjour, Jane Figueiredo, Jennifer T. Anger, Maurice Garcia, Peter R. Carroll, Matthew R. Cooperberg, Adriana C. Vidal, Stephen J. Freedland
Summary: The global population of transgender individuals is approximately 0.4-1.3%, and transgender women retain their prostates even after gender-affirmation surgery, requiring ongoing screening for prostate cancer. However, there is limited knowledge about prostate-specific antigen (PSA) screening in this population.
Article
Medicine, Research & Experimental
Celina H. Shirazipour, Carolina Raines, Marcio A. Diniz, Sarah-Jeanne Salvy, Robert W. Haile, Stephen J. Freedland, Arash Asher, Jennifer R. Tomasone, Gillian Gresham
Summary: Increased physical activity, improved sleep, and decreased sedentary behavior are crucial for cancer survivors. However, efforts to promote and measure these behaviors have been limited. The 24-Hour movement approach, which views physical activity, sedentary behavior, and sleep as a continuum, has potential benefits for clinical trial design and integration of wearable technology in oncology.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS
(2023)
Article
Critical Care Medicine
Hyung-Geun Moon, Seung-jae Kim, Ki-Hyun Kim, Young-Mee Kim, Jalees Rehman, Hyun Lee, Yi-Chien Wu, Steve Seung-Young Lee, John W. Christman, Steven J. Ackerman, Minhyung Kim, Sungyoung You, Gye Young Park
Summary: This study aims to investigate the cellular mechanism of tissue-resident macrophages involved in the resolution process of eosinophilic lung inflammation. Using mass cytometry, single-cell RNA sequencing, and biophysical and immunological analyses, it was found that the CCL26-CX3CR1 pathway plays a crucial role in resolving eosinophilic allergic lung inflammation.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2023)
Article
Cell Biology
Zhijun Wang, So Yeon Kim, Wei Tu, Jieun Kim, Alexander Xu, Yoon Mee Yang, Michitaka Matsuda, Lien Reolizo, Takashi Tsuchiya, Sandrine Billet, Alexandra Gangi, Mazen Noureddin, Ben A. Falk, Sungjin Kim, Wei Fan, Mourad Tighiouart, Sungyong You, Michael S. Lewis, Stephen J. Pandol, Dolores Di Vizio, Akil Merchant, Edwin M. Posadas, Neil A. Bhowmick, Shelly C. Lu, Ekihiro Seki
Summary: Liver metastasis is a major cause of death in colorectal cancer patients with fatty liver, but the underlying mechanism is unclear. Our study found that extracellular vesicles (EVs) derived from hepatocytes in fatty liver enhance the progression of CRC liver metastasis by promoting oncogenic Yes-associated protein (YAP) signaling and an immunosuppressive microenvironment. Fatty liver upregulates Rab27a expression, promoting EV production from hepatocytes. These EVs transfer YAP signaling-regulating microRNAs to cancer cells, augmenting YAP activity by suppressing LATS2.
Article
Endocrinology & Metabolism
Jordan J. Kramer, Lin Gu, Daniel Moreira, Gerald Andriole, Stephen J. Freedland, Ilona Csizmadi
Summary: In older men, smoking does not increase the risk of developing lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in asymptomatic men, nor does it affect the progression of LUTS in symptomatic men.
Article
Endocrinology & Metabolism
Victor Pereira, Taofik Oyekunle, Jessica Janes, Christopher J. Amling, William J. Aronson, Matthew R. Cooperberg, Christopher J. Kane, Martha K. Terris, Zachary Klaassen, Stephen J. Freedland, Adriana C. Vidal, Ilona Csizmadi
Summary: A study of 5885 patients at eight Veterans Affairs Hospitals found no significant differences in waiting time for prostate cancer treatment between Black and White men.
Article
Medicine, Research & Experimental
Yanping Wang, Yi Zhang, Shengchen Su, Patrick Tamukong, Ramachandran Murali, Hyung L. Kim
Summary: CD4+ regulatory T cells (Tregs) are crucial in controlling anti-tumor immune responses. A new PROTAC drug, PF, that targets the transcription factor FoxP3, has been developed. PF effectively decreases FoxP3 expression in Tregs, enhancing CD8+ lymphocyte proliferation and activation, as well as inhibiting tumor growth. PF also synergizes with immune checkpoint inhibitors and mTOR inhibitors to enhance antitumor immunity. This study provides important evidence for the potential use of PF in cancer immunotherapy.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Oncology
Ivy T. Liu, Lin Gu, Amanda M. De Hoedt, Matthew R. Cooperberg, Christopher L. Amling, Christopher J. Kane, Zachary Klaassen, Martha K. Terris, Lourdes Guerrios-Rivera, Adriana C. Vidal, William J. Aronson, Stephen J. Freedland, Ilona Csizmadi
Summary: This research examined the associations between obesity and various outcomes of prostate cancer, such as biochemical recurrence, metastasis, castrate resistant-PC, PCSM, and ACM. The study also investigated if smoking modified these associations. The results showed that obesity was associated with an increased risk of PCSM, while overweight and obesity were inversely associated with ACM. Additionally, the associations between BCR and ACM were modified by smoking status.
CANCER CAUSES & CONTROL
(2023)
Article
Allergy
Hyung-Geun Moon, Jacob D. Eccles, Seung-jae Kim, Ki-Hyun Kim, Young-Mee Kim, Jalees Rehman, Hyun Lee, Pinal Kanabar, John W. Christman, Steven J. Ackerman, Christian Ascoli, Homan Kang, Hak Soo Choi, Minhyung Kim, Sungyong You, Gye Young Park
Summary: C1q is selectively enriched in the CSF1R+cDC2 subset among conventional DCs, and it plays a critical role in allergen sensing and allergic lung inflammation. The C1q receptor CD91 (LRP1) is required for lung CSF1R+cDC2s to recognize the C1q-allergen complex and induce allergic lung inflammation.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2023)
Meeting Abstract
Oncology
Sanjay Das, Lin Gu, Claire Trustram Eve, Joshua Parrish, Amanda Marie De Hoedt, Chad McKee, William Aronson, Stephen J. Freedland, Stephen B. Williams
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Maral DerSarkissian, Deepshekhar Gupta, Jasmina Ivanova, Alexander Niyazov, Enrico Zanardo, Tracy Guo, Jingru Wang, Mei Sheng Duh, Stephen J. Freedland
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Maral DerSarkissian, Deepshekhar Gupta, Jasmina Ivanova, Alexander Niyazov, Enrico Zanardo, Tracy Guo, Jingru Wang, Mei Sheng Duh, Stephen J. Freedland
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Stephen J. Freedland, Alexander Niyazov, Jonathan Nazari, Evelyn Worthington, Austin Lansing, Emily Rosta, Imtiaz Samjoo
JOURNAL OF CLINICAL ONCOLOGY
(2023)
